Shire to License Rights for Pfizer’s IBD Drug PF-00547659

Shire to License Rights for Pfizer’s IBD Drug PF-00547659
The biotechnology company Shire will license global rights from Pfizer for PF-00547659, a drug under development for patients with moderate-to-severe inflammatory bowel disease (IBD). IBD is a group of conditions characterized by inflammation in the digestive tract, estimated to affect more than 3.5 million people in the U.S., European Union, and Japan. Two major types of IBD are ulcerative colitis and Crohn's disease, which usually cause symptoms such as pain, weigh loss, fatigue, and diarrhea. Treatment for IBD often focuses on reducing inflammation and disease symptoms. Pfizer's PF-00547659 is a monoclonal antibody that targets the adhesion molecule MAdCAM-1, expressed in the endothelial cells from the
Subscribe or to access all post and page content.

One comment

  1. tom says:

    To the Ian C. Read and Pfizer company. CBS anchor woman Cindy Hsu recently got involved in dirty coraption with infamous CBS anchor Otis Livingston to rob Pfizer company employees bank accounts. Never trust Cindy Hsu and Otis Livingston they are big problem for business and need to be arrested!!!!!!!!!!!!!!!!!

Leave a Comment

Your email address will not be published. Required fields are marked *